Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab - Eli Lilly and Company

Drug Profile

Cetuximab - Eli Lilly and Company

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California
  • Developer Array BioPharma; Bristol-Myers Squibb; Celldex Therapeutics Inc; Centre Jean Perrin; Eli Lilly; Eli Lilly and Company; Merck KGaA; New York University School of Medicine; Novartis; Pierre Fabre; Roche; UNICANCER; University Hospital Ghent; University of Heidelberg; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Mesothelioma; Rectal cancer; Squamous cell cancer
  • Phase I/II Adenoid cystic carcinoma; Solid tumours
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 02 Dec 2019 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Canada, Australia, USA (IV) (NCT04165031)
  • 30 Nov 2019 UNICANCER completes a phase-I/II clinical trials in Squamous cell cancer (Recurrent, Metastatic disease, Combination therapy, Late-stage disease, Second-line therapy or greater) in France (IV) (NCT02822482) (EudraCT2015-004340-19)
  • 19 Nov 2019 Eli Lilly and Company plans a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Australia, Canada, Spain (IV) (NCT04165031)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top